


下載本文檔
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESC66Cat. No.: HY-19832CAS No.: 871361-88-5分式: CHNO分量: 276.33作靶點(diǎn): Akt; Apoptosis作通路: PI3K/Akt/mTOR; Apoptosis儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 34 mg/mL (123.04 mM)* means solub
2、le, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.6189 mL 18.0943 mL 36.1886 mL5 mM 0.7238 mL 3.6189 mL 7.2377 mL10 mM 0.3619 mL 1.8094 mL 3.6189 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 SC66種 Akt 抑制劑,降低細(xì)胞活,這種作存在劑量和時(shí)間依賴(lài)性,且抑制肝癌 (HCC) 細(xì)胞的集落形成和誘
3、導(dǎo)凋亡。IC50 & Target Akt體外研究SC66 inhibits cell viability and colony forming capacity of HCC cells with IC50s of 0.77,0.47,0.92,0.751/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEand 2.85 g/mL at 72 hours for HepG2, Hep3B, PLC/PRF/5,HA22T/VGH and Huh7 cells. HepG2,HA22T/VGH and PLC/PRF/5 cells have si
4、milar IC50s of approximately 0.85 and 0.75 g/mL at 48 and 72hours, respectively. To determine whether the decrease in cell viability is related to apoptosis induction,TUNEL assays are performed in Hep3B and Huh7 cells treated with 1, 2 and 4 g/mL of SC66 for 24 hours.In Hep3B cells the number of TUN
5、EL-positive cells increased with increasing concentrations of SC66,whereas in Huh7 cells very few light brown-colored cells are observed only after treatment with 4 g/mLSC66 1.體內(nèi)研究 To demonstrate the effectiveness in vivo of SC66 on HCC, a mouse xenograft tumor model of Hep3B cells isused. When tumo
6、rs became palpable, at a size of about 150 mm3, mice are randomized into three groups of6 animals each. The treated group receive SC66 at 15 and 25 mg/kg twice a week via i.p. injection, while theuntreated group receive the vehicle alone. Treatment with 25 mg/Kg SC66 significantly reduces tumorvolum
7、e to 37% on day 17 when compared with tumors of the untreated group 1.PROTOCOLCell Assay 1 Cells (5 103/well) are distributed into each well of 96-well microtiter plates and then incubated overnight. Attime 0, the medium is replaced with fresh complete medium and different doses of SC66 are added. C
8、ells arecultured for 24, 48 and 72 hours. At the end of treatment, MTS assays are performed using the CellTiterAqueous OneSolution kit. Cell viability is expressed as a percentage of the absorbance measured in thecontrol cells. Values are expressed as meansSD of three separate experiments, each perf
9、ormed in triplicate1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Male nude athymic mice (Fox1 nu/nu) aged 4 weeks are used. Suspensions of 1107 Hep3B cells in 0.2 mLof PBS are inoculated into the right flank of the anim
10、al. When tumors became palpable (around 150 mm3),the mice are randomly divided into three groups of 6 animals each, with the various tumor volumes equallydistributed among the three groups. Two groups of mice are treated twice a week with 15 and 25 mg/kgSC66 suspended in DMSO, further diluted in a s
11、olution of 25% ethanol and administered via i.p. injection.The control group receive the vehicle alone. Tumor volumes are determined twice a week using calipers.Primary tumor volumes are calculated.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Cusimano A, et al. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015Jan 30;6(3):1707-22.McePdfHeightCaution: Product
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 書(shū)制作合同范例
- 包工合同范例
- 化工材料購(gòu)銷(xiāo)合同范例
- 單位買(mǎi)社保勞動(dòng)合同范例
- 個(gè)人買(mǎi)賣(mài)電器合同范例
- 使用空調(diào)合同范例
- 原油進(jìn)口合同范例
- 出售苗圃基地合同范例
- 公路清障租賃合同范例
- 養(yǎng)殖牛合同范例
- 中國(guó)近現(xiàn)代史綱要學(xué)習(xí)心得體會(huì)與社會(huì)責(zé)任
- 圖解《弘揚(yáng)教育家精神》全文課件
- 2025年廣州體育職業(yè)技術(shù)學(xué)院高職單招高職單招英語(yǔ)2016-2024年參考題庫(kù)含答案解析
- 2025年山西地質(zhì)集團(tuán)社會(huì)招聘高頻重點(diǎn)提升(共500題)附帶答案詳解
- 課題申報(bào)參考:援藏口述史思想政治教育價(jià)值的挖掘與應(yīng)用研究
- 陜煤集團(tuán)榆林化學(xué)有限責(zé)任公司招聘筆試
- 2024年南陽(yáng)農(nóng)業(yè)職業(yè)學(xué)院?jiǎn)握新殬I(yè)技能測(cè)試題庫(kù)及解析答案
- 2025年中國(guó)電信山東分公司招聘筆試參考題庫(kù)含答案解析
- 中國(guó)糖尿病防治指南(2024版)解讀-1
- 2024年計(jì)算機(jī)二級(jí)WPS考試題庫(kù)(共380題含答案)
- 漢字的奧秘探索
評(píng)論
0/150
提交評(píng)論